"Important difference" for interpreting health-related quality of life outcome measures: Important to whom?

Supportive Care in Cancer

Volumn 20, Issue 3, 2012, Pages 429-431

  Wu, Jackson S Y ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED CANCER; ADVERSE OUTCOME; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL EVALUATION; DISEASE SEVERITY; EDITORIAL; FUNCTIONAL ASSESSMENT; FUNCTIONAL STATUS; INSTRUMENT VALIDATION; MEASUREMENT ERROR; OUTCOME ASSESSMENT; PATIENT ADVOCACY; PATIENT CARE PLANNING; PRIORITY JOURNAL; PROCESS DEVELOPMENT; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM;

DATA INTERPRETATION, STATISTICAL; HUMANS; NEOPLASMS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PHYSICIAN-PATIENT RELATIONS; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 84857646560     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-011-1350-2     Document Type: Editorial

References (14)

1. S Kassa JH Loge 2003 Quality of life in palliative care: principles and practice Pall Med 17 11 20 10.1191/0269216303pm662ra (Pubitemid 36193216)
2. NK Aaronson S Ahmedzai B Bergman, et al. 1993 The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology J Natl Cancer Inst 85 365 376 8433390 10.1093/jnci/85.5.365 1:STN:280:DyaK3s7msVarsQ%3D%3D (Pubitemid 23073154)
3. B Kirshner GH Guyatt 1985 A methodological framework for assessing health indices J Chron DIs 38 1 27 36 3972947 10.1016/0021-9681(85)90005-0 1:STN:280:DyaL2M7jtFGmtA%3D%3D (Pubitemid 15136767)
4. Streiner DL, Norman GR (2003) Health measurement scales: a practice guide to their development and use, 3rd edn. Oxford University Press, Oxford
5. HJ Schunemann GH Guyatt 2005 Commentary-goodbye M(C)ID! Hello MID, where do you come from? Health Serv Res 40 593 596 15762909 10.1111/j.1475-6773.2005. 0k375.x (Pubitemid 40470710)
6. RH Dworkin DC Turk W Wyrwich D Beaton CS Cleeland JT Farrar, et al. 2008 Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations J Pain 9 2 105 121 18055266 10.1016/j.jpain.2007.09.005 (Pubitemid 351147828)
7. D Revicki RD Hays D Cella J Sloan 2008 Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes J Clin Epi 61 102 109 10.1016/j.jclinepi.2007.03.012
8. DE Beaton C Bombardier JN Katz JG Wright 2001 A taxonomy of responsiveness J Clin Epi 54 1204 1217 10.1016/S0895-4356(01)00407-3 1:STN:280:DC%2BD38%2FgtlCrsw%3D%3D (Pubitemid 34002973)
9. NS Jacobson P Truax 1991 Clinical significance: a statistical approach to defining meaningful change in psychotherapy research J Consult Clin Psychol 59 12 19 2002127 10.1037/0022-006X.59.1.12 1:STN:280:DyaK3M7mtFOmsg%3D%3D
10. WJJ Hageman WA Arrindell 1999 Establishing clinically significant change: increment of precision and the distinction between individual and group level of analysis Behav Res Ther 37 1169 1193 10596464 10.1016/S0005-7967(99)00032-7 1:STN:280:DC%2BD3c%2FmsValsw%3D%3D (Pubitemid 29481790)
11. JT Maringwa C Quinten M King J Ringash D Osoba C Coens, et al. 2011 Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials Support Care Cancer 19 11 1753 1760 20886240 10.1007/s00520-010-1016-5
12. D Osoba G Rodrigues J Myles B Zee J Pater 1998 Interpreting the significance of changes in health-related quality-of-life scores J Clin Oncol 16 1 139 144 9440735 1:STN:280:DyaK1c7gtFKrtw%3D%3D (Pubitemid 28041591)
13. JS Temel JA Greer A Muzikansky ER Gallagher S Admane VA Jackson, et al. 2010 Early palliative care for patients with metastatic non-small cell lung cancer N Engl J Med 363 733 742 20818875 10.1056/NEJMoa1000678 1:CAS:528:DC%2BC3cXhtVCrt7nP
14. C Quinten C Coens M Mauer S Comte MAG Sprangers C Cleeland, et al. 2009 Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials Lancet Oncol 10 865 871 19695956 10.1016/S1470-2045(09)70200-1